Research And Views Archives | Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Archives... Don't Miss Anything, Ever!

Here you will find all the research and views that we post on Equitymaster. Use the tools to customize the results to suit your preference!


















Authors
 

Pfizer Share price, NSE/BSE Forecast News and Quotes| Equitymaster

Oct 18, 2021 | Updated on Oct 18, 2021

Pfizer: Get the latest Pfizer Share price and stock price updates, live NSE/BSE share price, share market reports, financial report, balance sheet, price charts, financial forecast news and quotes only at Equitymaster.com.

MNC Pharma: And the performers are...

Sep 6, 2005

The first half of the year has gone by and MNC pharma companies, which largely follow a calendar year, have managed to stage a comeback after the difficult first quarter (March 2005 ending), which was plagued by VAT related issues. In this article, we compare the 1HFY06 performance of the 4 MNC pharma companies under our research coverage viz., Pfizer, Abbott India (both November ending), Glaxo and Aventis (both December ending).

Pfizer: Bright future ahead?

Jun 10, 2005

With the product patent regime now in force in India from the start of 2005, MNC pharma companies stand to gain as new product launches will spur growth for these companies in the coming years. MNC pharma major Pfizer is one of these companies. In this article, we take a look at the past performance of the company and future prospects.

Pfizer: On the course

Sep 27, 2004

Pfizer India has declared its 3QFY05 results (November year ending). The net profit of the company has grown by 15 % in the August quarter, although this has to be viewed in the context of a lacklustre performance last year. The operating margins have improved by 110 basis points to 12.7% compared to 11.6% in the same quarter last year. The net profit margin has also improved by 150 basis points to 10.6%. The operating margin for 9mFY05 was also better, with an improvement of 420 basis points to

Pfizer: Coming back to health

Sep 21, 2004

Pfizer India is one of the leading MNC pharma companies operating in India. It is a 40% subsidiary of the world's largest pharma company Pfizer Inc, which had sales of US$ 40 bn in 2003. It is a leading company in the Indian markets with key brands such as Corex (a cough syrup) and Becosules (a B-complex supplement), the two being brands with a revenue of over Rs 1 bn each. Most of the company’s products are OTC (over the counter) products with strong brand equity.

MNC pharma: The opportunity

Sep 14, 2004

There are many MNC pharma companies operating in India. While some of them have really entrenched themselves in the country, others are involved more in being a trading entity. Companies such as Aventis, Glaxo and Pfizer have full fledged operations in India, others like Abbott, Sanofi, Novartis are more or less trading companies. This is one of the major criteria that also determine the depth of these companies in the Indian market place. In this article, we review the MNC companies that are pr

Pharma: Global Vs local

Jun 10, 2004

There are two types of companies in the Indian pharma industry. While some are subsidiaries of global giants, others are home grown companies. Glaxo, Pfizer, Aventis and Novartis fall in the former category, while Ranbaxy, Cipla, Dr Reddy's, Wockhardt and Nicholas Piramal fall in the latter. Let's compare their business models and their performance.

MNC Pharma: A comparison

Oct 14, 2003

In an article in our series on identifying stocks, we had discussed the key parameters that should be looked into while investing in an MNC pharma stock. In this article, we have analyzed some of the leading MNC pharma companies (GlaxoSmithKline Pharma, Pfizer, Aventis, Novartis and Abbott India) on the basis of some of the parameters that were mentioned in that article. Take a look at the following t

Pfizer: Dismal performance

Sep 30, 2003

After a long delay Pfizer announced its 1QFY04, 2QFY04 and 3QFY04 results recently. The company was earlier restrained from announcing the same due to litigations filed by dissenting shareholders of Parke-Davis over its merger with the latter company. For 3QFY04, while the topline has declined marginally by 1%, bottomline has dropped 40%. For 9mFY04, Pfizer has recorded a 7% decline in topline and a massive 60% drop in bottomline. In this context, let us take a detailed look at the company’s per

Pfizer: Playing the waiting game

Jul 9, 2003

Over the years, MNC pharma companies have seen steady erosion in their share in the domestic pharma market. From a market share (in value terms) of almost 90% in the 70s, MNC pharma companies now barely account for 20% of domestic pharma sales. Absence of product patents and a consequent reluctance in launching new products coupled with rigid price controls has been the key reasons for this erosion in market share. Pfizer ltd has been no exception to this scenario.

Pfizer: Is the giant turning?

Oct 4, 2002

In a spate of three years, Pfizer Inc has tripled its revenue base backed by path breaking acquisition of Warner Lambert and Pharmacia. The total acquisition cost for these two subsidiaries was in excess of US$ 150 bn!

Pfizer Inc: A behemoth in the making

Jul 16, 2002

Call it a lesson in how sheer size can make a strategic difference in the pharma industry. In yet another display of company’s aggressiveness to stay on top, Pfizer Inc has declared a mega buyout of Pharmacia for US$ 60 bn in an all-stock deal. It was only in early 2000 that the company bought over Warner Lambert for US$ 90 bn, to snatch the top position in the global pharma industry.

Pfizer: Gearing up

Jul 4, 2002

Pfizer has reported a marginal rise in net sales (excluding excise) for 1HFY03 ahead of its merger with Parke Davis. This seems mainly on the back of discontinuance of certain non-profitable brands ahead of the merger. The merger ratio has been finalised at 4:9 (i.e. 4 shares of Pfizer for every 9 shares of Parke Davis). Post the merger, Pfizer is expected to be the fifth largest player in the domestic pharma market.

Pfizer: Merger picture

Jun 27, 2002

Pfizer Inc. emerged as the world's largest pharma company in early 2000, when it snatched Warner Lambert from the clutches of rival suitor American Home Products (AHP). A US$ 90 bn acquisition of Warner Lambert was the largest ever in the history of global pharma industry. The merged entity now has sales close to US$ 30 bn with highest R&D budget in the pharma industry.

Pfizer: Margins on the rise

Mar 19, 2002

Apparently, on the back of strong marketing push, Pfizer has logged a 6.6% topline growth in 1QFY03. The growth has been marginally better than our expectations. The highlight of the results was a sharp improvement in operating margins compared to the last year by more than 570 basis points.

Pfizer: FY02 net rises 20%

Jan 29, 2002

Pfizer has declared a net profit growth of 20% for the year ended November'01 as against 11% growth in sales. There is has been a marginal rise in operating margins of the company to 7.2% from 6.3% last year. Equity captial has gone up due to bonus issue last year.

Pfizer: 3QFY02 net up 14%

Sep 26, 2001

Pfizer, has declared 14% rise in net profit for Q3FY02 (quarter ending in Aug'01). The rise in net profits was mainly on the back of 40 basis points increase in operating margins and a spurt in other income. The third quarter performance for the company is usually the best as sales of cold and cough preparations pick up during this quarter. However, a flat sales growth was quite disappointing.

Pfizer: 2QFY02 net zooms 37%

Jun 30, 2001

Pfizer has declared an encouraging net profit growth of 37% for 2QFY02 as against 19% growth in sales. Operating margins of the company have shot up to 9.6%.The performance of the company has been better than expected. The third quarter performance is usually the best as sales of cold and cough preparations pick up during this quarter. An increase in operating margins in the second quarter has therefore, come as a pleasant surprise.

Pfizer: 1QFY02 net zooms 33%

Apr 2, 2001

Pfizer India has reported a 33% jump in its bottomline during the first quarter ended February 28, 2001. A 44% jump in other income has been partly responsible for the growth in bottomline.

Pfizer net up 27%

Feb 6, 2001

Pfizer has reported a 27% rise in the net profit on the back of a 11% growth in the turnover. While the detailed results are awaited, a part of the rise in the net profits could also be due to lower write off of the VRS expenditure in the current year.


Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

MARKET STATS